[go: up one dir, main page]

PL3622953T3 - Leczenie skojarzone nowotworu - Google Patents

Leczenie skojarzone nowotworu

Info

Publication number
PL3622953T3
PL3622953T3 PL19205104T PL19205104T PL3622953T3 PL 3622953 T3 PL3622953 T3 PL 3622953T3 PL 19205104 T PL19205104 T PL 19205104T PL 19205104 T PL19205104 T PL 19205104T PL 3622953 T3 PL3622953 T3 PL 3622953T3
Authority
PL
Poland
Prior art keywords
cancer therapy
combined cancer
combined
therapy
cancer
Prior art date
Application number
PL19205104T
Other languages
English (en)
Polish (pl)
Inventor
Nils Aage Brünner
Palle Christophersen
Jan Stenvang
Jens Lichtenberg
Annemette Thougaard
Original Assignee
Scandion Oncology A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology A/S filed Critical Scandion Oncology A/S
Publication of PL3622953T3 publication Critical patent/PL3622953T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19205104T 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu PL3622953T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17
EP19205104.3A EP3622953B1 (fr) 2016-05-17 2017-05-17 Polythérapie du cancer
EP17726573.3A EP3458052B1 (fr) 2016-05-17 2017-05-17 Polythérapie du cancer
PCT/EP2017/061823 WO2017198700A1 (fr) 2016-05-17 2017-05-17 Polythérapie du cancer

Publications (1)

Publication Number Publication Date
PL3622953T3 true PL3622953T3 (pl) 2021-08-16

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19205104T PL3622953T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu
PL17726573T PL3458052T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17726573T PL3458052T3 (pl) 2016-05-17 2017-05-17 Leczenie skojarzone nowotworu

Country Status (19)

Country Link
US (2) US11103481B2 (fr)
EP (3) EP3854393A1 (fr)
JP (1) JP7033554B2 (fr)
CN (4) CN109475535A (fr)
AU (1) AU2017266724B2 (fr)
BR (1) BR112018073518A2 (fr)
CA (1) CA3023202A1 (fr)
CY (2) CY1122541T1 (fr)
DK (2) DK3622953T3 (fr)
ES (2) ES2870805T3 (fr)
HR (2) HRP20200076T1 (fr)
HU (2) HUE047542T2 (fr)
LT (2) LT3622953T (fr)
PL (2) PL3622953T3 (fr)
PT (2) PT3458052T (fr)
RS (2) RS61786B1 (fr)
SI (2) SI3622953T1 (fr)
SM (2) SMT202000053T1 (fr)
WO (1) WO2017198700A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475535A (zh) * 2016-05-17 2019-03-15 斯坎丁肿瘤公司 癌症的联合治疗
US11530181B2 (en) 2018-02-22 2022-12-20 University Of Florida Research Foundation, Incorporated IL-6 inhibitors and methods of treatment
EP3846802A1 (fr) * 2018-09-06 2021-07-14 Scandion Oncology A/S Dérivés d'urée destinés à être utilisés dans le traitement de sujets présentant une expression et/ou une activité élevées de srpk1
WO2020079051A1 (fr) 2018-10-16 2020-04-23 Scandion Oncology A/S Composés pour le traitement d'une infection microbienne
WO2022263411A1 (fr) 2021-06-14 2022-12-22 Scandion Oncology A/S Traitements combinés pour patients atteints d'un cancer et procédés d'identification de ceux-ci
WO2022263404A1 (fr) 2021-06-14 2022-12-22 Scandion Oncology A/S Procédés d'augmentation de l'exposition médicamenteuse plasmatique d'agents anticancéreux
EP4104834A1 (fr) 2021-06-14 2022-12-21 Scandion Oncology A/S Combinaison de traitements pour des patients atteints de cancer et procédés d'identification associés
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (fr) 2021-12-20 2023-06-21 Scandion Oncology A/S Combinaison de médicaments pour le traitement du cancer
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (fr) 2022-06-14 2023-12-21 Scandion Oncology A/S Inhibiteur d'abcg2 et inhibiteur de nae pour le traitement du cancer
WO2024013058A1 (fr) 2022-07-11 2024-01-18 Scandion Oncology A/S Sels de sco-101 et procédés faisant intervenir des sels
WO2025125679A1 (fr) 2023-12-15 2025-06-19 Scandion Oncology A/S Régime de traitement anticancéreux amélioré

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
RU2197482C2 (ru) 1997-04-22 2003-01-27 НьюроСёрч А/С Замещенные фенильные производные, способ их получения, содержащая их фармацевтическая композиция и способ лечения (варианты)
EE04849B1 (et) 1998-10-22 2007-06-15 Neurosearch A/S Asendatud fenüülderivaadid, nende valmistamine jakasutamine
DE60316297T2 (de) 2002-08-01 2008-06-19 Neurosearch A/S Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
DE602004017175D1 (de) * 2003-06-17 2008-11-27 Neurosearch As Diphenylurea-derivative und ihre verwendung als chloridkanalblocker
EP1713809B1 (fr) 2004-02-04 2009-07-29 Neurosearch A/S Composes azacycliques dimeres et leur utilisation
JP2008524158A (ja) 2004-12-17 2008-07-10 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化剤として有用なジフェニル尿素誘導体
KR20080103106A (ko) * 2006-03-14 2008-11-26 뉴로서치 에이/에스 디페닐우레아 유도체 및 클로라이드 채널 차단제 또는 ＢＫＣａ 채널 조정자로서의 이의 용도
PA8852901A1 (es) * 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (fr) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Protéines et complexes protéiques lrrc8 et procédés d'identification de modulateurs de canal
EP3064207B1 (fr) 2015-03-04 2017-12-20 Scandion Oncology A/S Dérivés de 4-amino-3-phenylamino-6-phenylpyrazolo [3,4-d]pyrimidine utilisés en tant qu'inhibiteurs de bcrp dans des traitements thérapeutiques
CN109475535A (zh) * 2016-05-17 2019-03-15 斯坎丁肿瘤公司 癌症的联合治疗

Also Published As

Publication number Publication date
WO2017198700A1 (fr) 2017-11-23
AU2017266724B2 (en) 2022-04-14
CN119564679A (zh) 2025-03-07
AU2017266724A1 (en) 2018-12-20
SMT202100245T1 (it) 2021-05-07
RS61786B1 (sr) 2021-06-30
HUE047542T2 (hu) 2020-04-28
HRP20210572T1 (hr) 2021-05-14
DK3622953T3 (da) 2021-04-26
SI3458052T1 (sl) 2020-04-30
EP3458052A1 (fr) 2019-03-27
CN119548493A (zh) 2025-03-04
ES2770374T3 (es) 2020-07-01
EP3622953A1 (fr) 2020-03-18
LT3458052T (lt) 2020-02-10
ES2870805T3 (es) 2021-10-27
SI3622953T1 (sl) 2021-05-31
PL3458052T3 (pl) 2020-06-29
CN119548494A (zh) 2025-03-04
JP7033554B2 (ja) 2022-03-10
US11903927B2 (en) 2024-02-20
CY1124242T1 (el) 2022-07-22
RS59844B1 (sr) 2020-02-28
US20190269654A1 (en) 2019-09-05
EP3622953B1 (fr) 2021-03-17
PT3458052T (pt) 2020-02-03
JP2019519506A (ja) 2019-07-11
HUE053744T2 (hu) 2021-07-28
LT3622953T (lt) 2021-04-26
US11103481B2 (en) 2021-08-31
BR112018073518A2 (pt) 2019-03-19
PT3622953T (pt) 2021-04-21
DK3458052T3 (da) 2020-02-03
EP3854393A1 (fr) 2021-07-28
CN109475535A (zh) 2019-03-15
SMT202000053T1 (it) 2020-03-13
CA3023202A1 (fr) 2017-11-23
CY1122541T1 (el) 2021-01-27
US20210353596A1 (en) 2021-11-18
EP3458052B1 (fr) 2019-11-06
HRP20200076T1 (hr) 2020-04-03

Similar Documents

Publication Publication Date Title
EP3651772A4 (fr) Polythérapie anticancéreuse
EP3463464A4 (fr) Traitement d'association
IL255261A0 (en) Methods for treating cancer
HUE053903T2 (hu) Kombinációs terápia rák ellen
HUE054012T2 (hu) Kombinációs terápia rák ellen
PL3458052T3 (pl) Leczenie skojarzone nowotworu
HUE059694T2 (hu) Készítmény rák kezelésére
DK3423087T3 (da) Kombinationsterapi mod cancer
IL263802A (en) Cancer treatment combinations
KR20180084772A (ko) 암 치료를 위한 조합 치료법
IL265697B1 (en) Treatment of prostate cancer
EP3413927A4 (fr) Cancérothérapie
IL264443A (en) Methods of treating prostate cancer
DK3768830T5 (da) Cancerterapi
IL268463A (en) Cancer treatment
EP3593139C0 (fr) Biomarqueurs du cancer
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline
DK3408265T3 (da) Terapeutiske forbindelser
HUE040167T2 (hu) Rákkezelés
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3362091A4 (fr) Polythérapie
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3407909T3 (da) Cancerbehandling